Evaluation of PAP in EGFR Mutational Testing in Advanced NSCLC: a Comparative Study

Clin Lab. 2019 Nov 1;65(11). doi: 10.7754/Clin.Lab.2019.190216.

Abstract

Background: EGFR mutational testing is crucial for advanced non-squamous NSCLC. PAP is a sensitive and selective method to detect rare mutations.

Methods: Eighty-five patients with non-squamous NSCLC were enrolled in this study. A set of paired plasma samples from each patient were collected and detected by PAP and ARMS.

Results: Of 85 paired samples, 78.8% (67/85) presented the same mutational status by the two methods. There was no statistically significant difference between the mutation frequencies in plasma samples detected with PAP and ARMS (p = 0.096).

Conclusions: PAP technology appears to be an alternative choice with relatively high sensitivity for the detection of plasma EGFR mutations.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • DNA Mutational Analysis / methods*
  • ErbB Receptors / blood
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation Rate
  • Mutation*
  • Predictive Value of Tests
  • Prospective Studies
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • EGFR protein, human
  • ErbB Receptors